Effects of IVIG for BPD in Preterm Infant Born at 28 Weeks and Below
Recruiting
Phase 2
Interventional Study
Bronchopulmonary Dysplasia
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
Prior Safety Data
This treatment has already been tested in at least one earlier human trial.
Healthy Volunteers Welcome
You do not need to have the condition being studied to take part.
At a Glance
- Age
- 1 Day – 10 Weeks
- Sex
- Any
- Trial phase
- Phase 2
- Study type
- Interventional
- Purpose
- Treatment
- Participants needed
- 29 (estimated)
- Sponsor
- International Peace Maternity and Child Health Hospital · Other
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
It is intended to examine the short-term and long-term efficacy and safety of intravenous immunoglobulin(IVIG) for the bronchopulmonary dysplasia in preterms born at 28 weeks and below. Participants will received continuous infusion IVIG 1 g/kg/day for the first 2 days, 0.5 g/kg/day for next 3 days (total does 3.5 g/kg), repeatable if necessary.
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
* Gestational age ≤ 28 weeks + 6 days
* Admission within 24 hours after birth.
* Clinical presentation and chest X radiograph changes of BPD
Clinical presentation: The respiratory symptoms and signs developed within several days or weeks after birth, such as shortness of breath…
Contacts